Compare The Coca-Cola Co K (KO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs GeneDx Holdings Corp — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: The Coca-Cola Co K is far larger — about 186.9× GeneDx Holdings Corp's market cap, and The Coca-Cola Co K pays a 2.42% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and GeneDx Holdings Corp for 19 Days on average.
| KO | WGS | |
|---|---|---|
Market Cap | $377.63B | $2.02B |
Volume | 14,894,568 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $167.51 |
52-Week Low | $66.37 | $34.51 |
Typical Hold Time | 154 Days | 19 Days |
Enterprise Value | $404.81B | $2.05B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.
KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
